AGENT FOR INDUCING SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 IN LIQUID FORM (VARIANTS)
The invention relates to a biomolecule agent for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2, in liquid form, which contains a single active component, comprising the expression vector including either: the genome of the recombinant strain of human adenoviru...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | TOKARSKAYA, Elizaveta Alexsandrovna NARODITSKY, Boris Savelievich GROUOVA, Daria Mikhailovna ZUBKOVA, Olga Vadimovna ESMAGAMBETOV, Ilias Bulatovich POPOVA, Olga BORISEVICH, Sergey Vladimirovich TUKHVATULIN, Amir Ildarovich TUKHVATULINA, Natalia Mikhailovna BOTIKOV, Andrei Gennadevich DZHARULLAEVA, Alina Shahmirovna IZHAEVA, Fatima Magometovna SHCHERBININ, Dmitrii Nikolaevich GINTSBURG, Aleksandr Leonidovich OZHAROVSKAIA, Tatiana Andreevna NIKITENKO, Natalya Anatolevna LOGUNOV, Denis Yuryevich DOLZHIKOVA, Inna Vadimovna SHCHEBLIAKOV, Dmitrii Viktorovich EROXOVA, Alina Sergeevna SEMIKHIN, Aleksandr Sergeevich LUBENETS, Nadezhda Leonidovna |
| description | The invention relates to a biomolecule agent for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2, in liquid form, which contains a single active component, comprising the expression vector including either: the genome of the recombinant strain of human adenovirus serotype 26 or 5, wherein the E1 and E3 regions are deleted, the vector with an integrated expression cassette is selected from SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3; or the recombinant strain of simian adenovirus serotype 25, wherein the E1 and E3 regions are deleted, the vector with an integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, or SEQ ID NO:3. The recombinant strain of human adenovirus serotype 26 may include the ORF6-Ad26 region replaced by ORF6-Ad5.A buffer solution of the agent in liquid form contains the following, by mass %: tris from 0.1831 to 0.3432; sodium chloride from 0.3313-0.6212; sucrose from 3.7821-7.0915; magnesium chloride hexahydrate from 0.0154-0.0289; EDTA from 0.0029-0.0054; polysorbate-80 from 0.0378-0.0709; ethanol 95% from 0.0004-0.0007; and water to fill.The agent can be administered via intranasal and/or intramuscular routes. The invention promotes humoral and cell-mediated immune responses against SARS-CoV-2 virus among broad strata of the population. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US2022259618A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US2022259618A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US2022259618A13</originalsourceid><addsrcrecordid>eNqNjTEKwkAQANNYiPqHBRstAnqiaLlcNnHBXOLuXSCViJyVaCA2_l4FH2A1zTAzTF5YkPOQVwLssmDZFaA1Wc7ZApdlcOxbwALZqQelhoQAbfAEQlqzoK-kBW1dJlVJ0LAEBUXR1FZNaj5VOPAxcPZ9lDBrUBid1_k4GVzPtz5Ofhwl05y83aexe5xi350v8R6fp6BmYYxZ7zbLLS5X_1lv0a47UQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>AGENT FOR INDUCING SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 IN LIQUID FORM (VARIANTS)</title><source>esp@cenet</source><creator>TOKARSKAYA, Elizaveta Alexsandrovna ; NARODITSKY, Boris Savelievich ; GROUOVA, Daria Mikhailovna ; ZUBKOVA, Olga Vadimovna ; ESMAGAMBETOV, Ilias Bulatovich ; POPOVA, Olga ; BORISEVICH, Sergey Vladimirovich ; TUKHVATULIN, Amir Ildarovich ; TUKHVATULINA, Natalia Mikhailovna ; BOTIKOV, Andrei Gennadevich ; DZHARULLAEVA, Alina Shahmirovna ; IZHAEVA, Fatima Magometovna ; SHCHERBININ, Dmitrii Nikolaevich ; GINTSBURG, Aleksandr Leonidovich ; OZHAROVSKAIA, Tatiana Andreevna ; NIKITENKO, Natalya Anatolevna ; LOGUNOV, Denis Yuryevich ; DOLZHIKOVA, Inna Vadimovna ; SHCHEBLIAKOV, Dmitrii Viktorovich ; EROXOVA, Alina Sergeevna ; SEMIKHIN, Aleksandr Sergeevich ; LUBENETS, Nadezhda Leonidovna</creator><creatorcontrib>TOKARSKAYA, Elizaveta Alexsandrovna ; NARODITSKY, Boris Savelievich ; GROUOVA, Daria Mikhailovna ; ZUBKOVA, Olga Vadimovna ; ESMAGAMBETOV, Ilias Bulatovich ; POPOVA, Olga ; BORISEVICH, Sergey Vladimirovich ; TUKHVATULIN, Amir Ildarovich ; TUKHVATULINA, Natalia Mikhailovna ; BOTIKOV, Andrei Gennadevich ; DZHARULLAEVA, Alina Shahmirovna ; IZHAEVA, Fatima Magometovna ; SHCHERBININ, Dmitrii Nikolaevich ; GINTSBURG, Aleksandr Leonidovich ; OZHAROVSKAIA, Tatiana Andreevna ; NIKITENKO, Natalya Anatolevna ; LOGUNOV, Denis Yuryevich ; DOLZHIKOVA, Inna Vadimovna ; SHCHEBLIAKOV, Dmitrii Viktorovich ; EROXOVA, Alina Sergeevna ; SEMIKHIN, Aleksandr Sergeevich ; LUBENETS, Nadezhda Leonidovna</creatorcontrib><description>The invention relates to a biomolecule agent for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2, in liquid form, which contains a single active component, comprising the expression vector including either: the genome of the recombinant strain of human adenovirus serotype 26 or 5, wherein the E1 and E3 regions are deleted, the vector with an integrated expression cassette is selected from SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3; or the recombinant strain of simian adenovirus serotype 25, wherein the E1 and E3 regions are deleted, the vector with an integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, or SEQ ID NO:3. The recombinant strain of human adenovirus serotype 26 may include the ORF6-Ad26 region replaced by ORF6-Ad5.A buffer solution of the agent in liquid form contains the following, by mass %: tris from 0.1831 to 0.3432; sodium chloride from 0.3313-0.6212; sucrose from 3.7821-7.0915; magnesium chloride hexahydrate from 0.0154-0.0289; EDTA from 0.0029-0.0054; polysorbate-80 from 0.0378-0.0709; ethanol 95% from 0.0004-0.0007; and water to fill.The agent can be administered via intranasal and/or intramuscular routes. The invention promotes humoral and cell-mediated immune responses against SARS-CoV-2 virus among broad strata of the population.</description><language>eng</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220818&DB=EPODOC&CC=US&NR=2022259618A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220818&DB=EPODOC&CC=US&NR=2022259618A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>TOKARSKAYA, Elizaveta Alexsandrovna</creatorcontrib><creatorcontrib>NARODITSKY, Boris Savelievich</creatorcontrib><creatorcontrib>GROUOVA, Daria Mikhailovna</creatorcontrib><creatorcontrib>ZUBKOVA, Olga Vadimovna</creatorcontrib><creatorcontrib>ESMAGAMBETOV, Ilias Bulatovich</creatorcontrib><creatorcontrib>POPOVA, Olga</creatorcontrib><creatorcontrib>BORISEVICH, Sergey Vladimirovich</creatorcontrib><creatorcontrib>TUKHVATULIN, Amir Ildarovich</creatorcontrib><creatorcontrib>TUKHVATULINA, Natalia Mikhailovna</creatorcontrib><creatorcontrib>BOTIKOV, Andrei Gennadevich</creatorcontrib><creatorcontrib>DZHARULLAEVA, Alina Shahmirovna</creatorcontrib><creatorcontrib>IZHAEVA, Fatima Magometovna</creatorcontrib><creatorcontrib>SHCHERBININ, Dmitrii Nikolaevich</creatorcontrib><creatorcontrib>GINTSBURG, Aleksandr Leonidovich</creatorcontrib><creatorcontrib>OZHAROVSKAIA, Tatiana Andreevna</creatorcontrib><creatorcontrib>NIKITENKO, Natalya Anatolevna</creatorcontrib><creatorcontrib>LOGUNOV, Denis Yuryevich</creatorcontrib><creatorcontrib>DOLZHIKOVA, Inna Vadimovna</creatorcontrib><creatorcontrib>SHCHEBLIAKOV, Dmitrii Viktorovich</creatorcontrib><creatorcontrib>EROXOVA, Alina Sergeevna</creatorcontrib><creatorcontrib>SEMIKHIN, Aleksandr Sergeevich</creatorcontrib><creatorcontrib>LUBENETS, Nadezhda Leonidovna</creatorcontrib><title>AGENT FOR INDUCING SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 IN LIQUID FORM (VARIANTS)</title><description>The invention relates to a biomolecule agent for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2, in liquid form, which contains a single active component, comprising the expression vector including either: the genome of the recombinant strain of human adenovirus serotype 26 or 5, wherein the E1 and E3 regions are deleted, the vector with an integrated expression cassette is selected from SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3; or the recombinant strain of simian adenovirus serotype 25, wherein the E1 and E3 regions are deleted, the vector with an integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, or SEQ ID NO:3. The recombinant strain of human adenovirus serotype 26 may include the ORF6-Ad26 region replaced by ORF6-Ad5.A buffer solution of the agent in liquid form contains the following, by mass %: tris from 0.1831 to 0.3432; sodium chloride from 0.3313-0.6212; sucrose from 3.7821-7.0915; magnesium chloride hexahydrate from 0.0154-0.0289; EDTA from 0.0029-0.0054; polysorbate-80 from 0.0378-0.0709; ethanol 95% from 0.0004-0.0007; and water to fill.The agent can be administered via intranasal and/or intramuscular routes. The invention promotes humoral and cell-mediated immune responses against SARS-CoV-2 virus among broad strata of the population.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjTEKwkAQANNYiPqHBRstAnqiaLlcNnHBXOLuXSCViJyVaCA2_l4FH2A1zTAzTF5YkPOQVwLssmDZFaA1Wc7ZApdlcOxbwALZqQelhoQAbfAEQlqzoK-kBW1dJlVJ0LAEBUXR1FZNaj5VOPAxcPZ9lDBrUBid1_k4GVzPtz5Ofhwl05y83aexe5xi350v8R6fp6BmYYxZ7zbLLS5X_1lv0a47UQ</recordid><startdate>20220818</startdate><enddate>20220818</enddate><creator>TOKARSKAYA, Elizaveta Alexsandrovna</creator><creator>NARODITSKY, Boris Savelievich</creator><creator>GROUOVA, Daria Mikhailovna</creator><creator>ZUBKOVA, Olga Vadimovna</creator><creator>ESMAGAMBETOV, Ilias Bulatovich</creator><creator>POPOVA, Olga</creator><creator>BORISEVICH, Sergey Vladimirovich</creator><creator>TUKHVATULIN, Amir Ildarovich</creator><creator>TUKHVATULINA, Natalia Mikhailovna</creator><creator>BOTIKOV, Andrei Gennadevich</creator><creator>DZHARULLAEVA, Alina Shahmirovna</creator><creator>IZHAEVA, Fatima Magometovna</creator><creator>SHCHERBININ, Dmitrii Nikolaevich</creator><creator>GINTSBURG, Aleksandr Leonidovich</creator><creator>OZHAROVSKAIA, Tatiana Andreevna</creator><creator>NIKITENKO, Natalya Anatolevna</creator><creator>LOGUNOV, Denis Yuryevich</creator><creator>DOLZHIKOVA, Inna Vadimovna</creator><creator>SHCHEBLIAKOV, Dmitrii Viktorovich</creator><creator>EROXOVA, Alina Sergeevna</creator><creator>SEMIKHIN, Aleksandr Sergeevich</creator><creator>LUBENETS, Nadezhda Leonidovna</creator><scope>EVB</scope></search><sort><creationdate>20220818</creationdate><title>AGENT FOR INDUCING SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 IN LIQUID FORM (VARIANTS)</title><author>TOKARSKAYA, Elizaveta Alexsandrovna ; NARODITSKY, Boris Savelievich ; GROUOVA, Daria Mikhailovna ; ZUBKOVA, Olga Vadimovna ; ESMAGAMBETOV, Ilias Bulatovich ; POPOVA, Olga ; BORISEVICH, Sergey Vladimirovich ; TUKHVATULIN, Amir Ildarovich ; TUKHVATULINA, Natalia Mikhailovna ; BOTIKOV, Andrei Gennadevich ; DZHARULLAEVA, Alina Shahmirovna ; IZHAEVA, Fatima Magometovna ; SHCHERBININ, Dmitrii Nikolaevich ; GINTSBURG, Aleksandr Leonidovich ; OZHAROVSKAIA, Tatiana Andreevna ; NIKITENKO, Natalya Anatolevna ; LOGUNOV, Denis Yuryevich ; DOLZHIKOVA, Inna Vadimovna ; SHCHEBLIAKOV, Dmitrii Viktorovich ; EROXOVA, Alina Sergeevna ; SEMIKHIN, Aleksandr Sergeevich ; LUBENETS, Nadezhda Leonidovna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US2022259618A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2022</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>TOKARSKAYA, Elizaveta Alexsandrovna</creatorcontrib><creatorcontrib>NARODITSKY, Boris Savelievich</creatorcontrib><creatorcontrib>GROUOVA, Daria Mikhailovna</creatorcontrib><creatorcontrib>ZUBKOVA, Olga Vadimovna</creatorcontrib><creatorcontrib>ESMAGAMBETOV, Ilias Bulatovich</creatorcontrib><creatorcontrib>POPOVA, Olga</creatorcontrib><creatorcontrib>BORISEVICH, Sergey Vladimirovich</creatorcontrib><creatorcontrib>TUKHVATULIN, Amir Ildarovich</creatorcontrib><creatorcontrib>TUKHVATULINA, Natalia Mikhailovna</creatorcontrib><creatorcontrib>BOTIKOV, Andrei Gennadevich</creatorcontrib><creatorcontrib>DZHARULLAEVA, Alina Shahmirovna</creatorcontrib><creatorcontrib>IZHAEVA, Fatima Magometovna</creatorcontrib><creatorcontrib>SHCHERBININ, Dmitrii Nikolaevich</creatorcontrib><creatorcontrib>GINTSBURG, Aleksandr Leonidovich</creatorcontrib><creatorcontrib>OZHAROVSKAIA, Tatiana Andreevna</creatorcontrib><creatorcontrib>NIKITENKO, Natalya Anatolevna</creatorcontrib><creatorcontrib>LOGUNOV, Denis Yuryevich</creatorcontrib><creatorcontrib>DOLZHIKOVA, Inna Vadimovna</creatorcontrib><creatorcontrib>SHCHEBLIAKOV, Dmitrii Viktorovich</creatorcontrib><creatorcontrib>EROXOVA, Alina Sergeevna</creatorcontrib><creatorcontrib>SEMIKHIN, Aleksandr Sergeevich</creatorcontrib><creatorcontrib>LUBENETS, Nadezhda Leonidovna</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>TOKARSKAYA, Elizaveta Alexsandrovna</au><au>NARODITSKY, Boris Savelievich</au><au>GROUOVA, Daria Mikhailovna</au><au>ZUBKOVA, Olga Vadimovna</au><au>ESMAGAMBETOV, Ilias Bulatovich</au><au>POPOVA, Olga</au><au>BORISEVICH, Sergey Vladimirovich</au><au>TUKHVATULIN, Amir Ildarovich</au><au>TUKHVATULINA, Natalia Mikhailovna</au><au>BOTIKOV, Andrei Gennadevich</au><au>DZHARULLAEVA, Alina Shahmirovna</au><au>IZHAEVA, Fatima Magometovna</au><au>SHCHERBININ, Dmitrii Nikolaevich</au><au>GINTSBURG, Aleksandr Leonidovich</au><au>OZHAROVSKAIA, Tatiana Andreevna</au><au>NIKITENKO, Natalya Anatolevna</au><au>LOGUNOV, Denis Yuryevich</au><au>DOLZHIKOVA, Inna Vadimovna</au><au>SHCHEBLIAKOV, Dmitrii Viktorovich</au><au>EROXOVA, Alina Sergeevna</au><au>SEMIKHIN, Aleksandr Sergeevich</au><au>LUBENETS, Nadezhda Leonidovna</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>AGENT FOR INDUCING SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 IN LIQUID FORM (VARIANTS)</title><date>2022-08-18</date><risdate>2022</risdate><abstract>The invention relates to a biomolecule agent for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2, in liquid form, which contains a single active component, comprising the expression vector including either: the genome of the recombinant strain of human adenovirus serotype 26 or 5, wherein the E1 and E3 regions are deleted, the vector with an integrated expression cassette is selected from SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3; or the recombinant strain of simian adenovirus serotype 25, wherein the E1 and E3 regions are deleted, the vector with an integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, or SEQ ID NO:3. The recombinant strain of human adenovirus serotype 26 may include the ORF6-Ad26 region replaced by ORF6-Ad5.A buffer solution of the agent in liquid form contains the following, by mass %: tris from 0.1831 to 0.3432; sodium chloride from 0.3313-0.6212; sucrose from 3.7821-7.0915; magnesium chloride hexahydrate from 0.0154-0.0289; EDTA from 0.0029-0.0054; polysorbate-80 from 0.0378-0.0709; ethanol 95% from 0.0004-0.0007; and water to fill.The agent can be administered via intranasal and/or intramuscular routes. The invention promotes humoral and cell-mediated immune responses against SARS-CoV-2 virus among broad strata of the population.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_US2022259618A1 |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE |
| title | AGENT FOR INDUCING SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 IN LIQUID FORM (VARIANTS) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T09%3A44%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=TOKARSKAYA,%20Elizaveta%20Alexsandrovna&rft.date=2022-08-18&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS2022259618A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |